BioCentury | Jul 11, 2020
Management Tracks

Andrews joins Akcea as CMO; plus changes at Strongbridge, Abeona, Lyra, Kronos and more

...antibody company’s expansion into the U.S. Knopf was CBO of Gemini Therapeutics Inc. Proteomics company IsoPlexis Corp....
...the mitochondrial disease company as a scientist in 2016. Robin Sawka, BioCentury Staff Akcea Therapeutics Inc. ImCheck Therapeutics S.A.S. IsoPlexis Corp. Abeona...
BioCentury | May 16, 2020
Management Tracks

Management Tracks: Evox, Phoenix Tissue Repair, Artax, Nucleix, IsoPlexis, Centogene, Immunicum, CohBar and CorMedix

...Miller was VP and head of the healthcare division at Stratasys Ltd. Single-cell analytics company IsoPlexis Corp....
...head of strategy at Ovid Therapeutics Inc. (NASDAQ:OVID). Robin Sawka, BioCentury Staff Evox Therapeutics Ltd. BridgeBio Artax Biopharma Inc. Nucleix Ltd. IsoPlexis Corp. Centogene Immunicum...
BioCentury | May 15, 2019
Financial News

May 15 Financial Quick Takes: Perceptive leads $60M round for ArcherDx; plus Applied Therapeutics’ IPO, IsoPlexis, Symphogen

...up $0.35. Series B investors return for IsoPlexis' $25M C round Single-cell immune biomarker company IsoPlexis Corp....
...options, including spin-offs or a potential sale of the company. Sandi Wong, Staff Writer Applied Therapeutics Inc. ArcherDx Inc. IsoPlexis Corp. Symphogen...
BioCentury | Sep 29, 2017
Financial News

Fusion, IsoPlexis, Tempus announce venture financings

...On Sept. 25, cancer company Fusion Pharmaceuticals Inc. (Hamilton, Ontario), single-cell analytics company IsoPlexis Corp. (Branford, Conn...
...Fusion’s linker technology and the alpha emitting cytotoxic isotope Actinium-225 (see BioCentury, Feb. 24 ). IsoPlexis...
...analytical machine-learning platform to personalize and improve cancer care. Fusion Pharmaceuticals Inc. , Hamilton, Ontario IsoPlexis Corp....
BioCentury | Sep 25, 2017
Financial News

Venture roundup: Fusion, IsoPlexis, Tempus

...On Monday, cancer company Fusion Pharmaceuticals Inc. (Hamilton, Ontario), single-cell analytics company IsoPlexis Corp. (Branford, Conn.) and...
...Fusion’s linker technology and the alpha emitting cytotoxic isotope Actinium-225 (see BioCentury, Feb. 23) . IsoPlexis...
...with an analytical machine-learning platform to personalize and improve cancer care. Jennie Walters FPX-01 SXC-2023 Fusion Pharmaceuticals Inc. Promentis Pharmaceuticals Inc. IsoPlexis Corp. Tempus...
Items per page:
1 - 5 of 5
BioCentury | Jul 11, 2020
Management Tracks

Andrews joins Akcea as CMO; plus changes at Strongbridge, Abeona, Lyra, Kronos and more

...antibody company’s expansion into the U.S. Knopf was CBO of Gemini Therapeutics Inc. Proteomics company IsoPlexis Corp....
...the mitochondrial disease company as a scientist in 2016. Robin Sawka, BioCentury Staff Akcea Therapeutics Inc. ImCheck Therapeutics S.A.S. IsoPlexis Corp. Abeona...
BioCentury | May 16, 2020
Management Tracks

Management Tracks: Evox, Phoenix Tissue Repair, Artax, Nucleix, IsoPlexis, Centogene, Immunicum, CohBar and CorMedix

...Miller was VP and head of the healthcare division at Stratasys Ltd. Single-cell analytics company IsoPlexis Corp....
...head of strategy at Ovid Therapeutics Inc. (NASDAQ:OVID). Robin Sawka, BioCentury Staff Evox Therapeutics Ltd. BridgeBio Artax Biopharma Inc. Nucleix Ltd. IsoPlexis Corp. Centogene Immunicum...
BioCentury | May 15, 2019
Financial News

May 15 Financial Quick Takes: Perceptive leads $60M round for ArcherDx; plus Applied Therapeutics’ IPO, IsoPlexis, Symphogen

...up $0.35. Series B investors return for IsoPlexis' $25M C round Single-cell immune biomarker company IsoPlexis Corp....
...options, including spin-offs or a potential sale of the company. Sandi Wong, Staff Writer Applied Therapeutics Inc. ArcherDx Inc. IsoPlexis Corp. Symphogen...
BioCentury | Sep 29, 2017
Financial News

Fusion, IsoPlexis, Tempus announce venture financings

...On Sept. 25, cancer company Fusion Pharmaceuticals Inc. (Hamilton, Ontario), single-cell analytics company IsoPlexis Corp. (Branford, Conn...
...Fusion’s linker technology and the alpha emitting cytotoxic isotope Actinium-225 (see BioCentury, Feb. 24 ). IsoPlexis...
...analytical machine-learning platform to personalize and improve cancer care. Fusion Pharmaceuticals Inc. , Hamilton, Ontario IsoPlexis Corp....
BioCentury | Sep 25, 2017
Financial News

Venture roundup: Fusion, IsoPlexis, Tempus

...On Monday, cancer company Fusion Pharmaceuticals Inc. (Hamilton, Ontario), single-cell analytics company IsoPlexis Corp. (Branford, Conn.) and...
...Fusion’s linker technology and the alpha emitting cytotoxic isotope Actinium-225 (see BioCentury, Feb. 23) . IsoPlexis...
...with an analytical machine-learning platform to personalize and improve cancer care. Jennie Walters FPX-01 SXC-2023 Fusion Pharmaceuticals Inc. Promentis Pharmaceuticals Inc. IsoPlexis Corp. Tempus...
Items per page:
1 - 5 of 5